Jason F Lester
Overview
Explore the profile of Jason F Lester including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
3761
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frankell A, Dietzen M, Al Bakir M, Lim E, Karasaki T, Ward S, et al.
Nature
. 2024 Jul;
631(8022):E15.
PMID: 38965439
No abstract available.
2.
Frankell A, Dietzen M, Al Bakir M, Lim E, Karasaki T, Ward S, et al.
Nature
. 2023 Apr;
616(7957):525-533.
PMID: 37046096
Lung cancer is the leading cause of cancer-associated mortality worldwide. Here we analysed 1,644 tumour regions sampled at surgery or during follow-up from the first 421 patients with non-small cell...
3.
Clarke C, Hunter R, Gabrio A, Brawley C, Ingleby F, Dearnaley D, et al.
PLoS One
. 2022 Jun;
17(6):e0269192.
PMID: 35653395
Adding abiraterone acetate (AA) plus prednisolone (P) to standard of care (SOC) improves survival in newly diagnosed advanced prostate cancer (PC) patients starting hormone therapy. Our objective was to determine...
4.
Hoskin P, Hopkins K, Misra V, Holt T, McMenemin R, McKinna F, et al.
Radiother Oncol
. 2022 May;
173:77-83.
PMID: 35618101
Background: Metastatic spinal cord compression (MSCC) carries a poor prognosis and management is based on the likelihood of maintaining mobility and predicted survival. Patients And Method: SCORAD is a randomised...
5.
Hussain S, Lester J, Jackson R, Gornall M, Qureshi M, Elliott A, et al.
Lancet Oncol
. 2022 Apr;
23(5):650-658.
PMID: 35421369
Background: Recurrence is common after neoadjuvant chemotherapy and radical treatment for muscle-invasive bladder cancer. We investigated the effect of adding nintedanib to neoadjuvant chemotherapy on response and survival in muscle-invasive...
6.
Fennell D, Ewings S, Ottensmeier C, Califano R, Hanna G, Hill K, et al.
Lancet Oncol
. 2021 Oct;
22(11):1530-1540.
PMID: 34656227
Background: No phase 3 trial has yet shown improved survival for patients with pleural or peritoneal malignant mesothelioma who have progressed following platinum-based chemotherapy. The aim of this study was...
7.
Shah R, Lester J
Clin Lung Cancer
. 2020 Feb;
21(3):e216-e228.
PMID: 32014348
The availability of 3 generations of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with different pharmacologic characteristics and clinical profiles has provided oncologists with a potentially confusing choice...
8.
Hoskin P, Hopkins K, Misra V, Holt T, McMenemin R, Dubois D, et al.
JAMA
. 2019 Dec;
322(21):2084-2094.
PMID: 31794625
Importance: Malignant spinal canal compression, a major complication of metastatic cancer, is managed with radiotherapy to maintain mobility and relieve pain, although there is no standard radiotherapy regimen. Objective: To...
9.
Collins J, Noble S, Davies H, Farewell D, Lester J, Parry D, et al.
Eur J Cancer Care (Engl)
. 2019 Feb;
28(3):e13004.
PMID: 30761639
Introduction: Clinician-rated performance status (C-PS) is used routinely to predict whether patients are fit enough to undergo treatment for lung cancer. However, a good proportion of those with seemingly good...
10.
Hatton M, Lawless C, Faivre-Finn C, Landau D, Lester J, Fenwick J, et al.
BMJ Open
. 2019 Feb;
9(1):e019903.
PMID: 30700475
Introduction: Lung cancer is the most common cause of cancer mortality in the UK, and non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Most patients present...